InterMune (ITMN) Says Esbriet Approved for Reimbursement in France
Tweet Send to a FriendGet Alerts ITMN Hot Sheet
Up)
Trade ITMN Now!
On September 11, 2012, InterMune, Inc. (Nasdaq: ITMN) announced that the Comité Economique des Produits de Santé (France’s Economic Committee on Health Care Products, or CEPS) has granted reimbursement for Esbriet (pirfenidone), making it the first medicine for the treatment of idiopathic pulmonary fibrosis (IPF) to be reimbursed in France. The price of Esbriet is expected to be published in France’s Journal Officiel in the fourth quarter of 2012, which is the final step in the reimbursement process for a new medicine in France.
The CEPS authorized an ex-factory reimbursed price of 1.923,08€ for a four-week treatment pack of Esbriet, corresponding to 25,000€ per patient, per year (approximately $32,000 USD at current exchange rates). Esbriet will be reimbursed by the French National Health Insurance system for the treatment of mild to moderate forms of IPF in adults.
Esbriet will be reimbursed as a “Médicament d’Exception,” which means that it will be reimbursed only for the labeled indication, defined previously by the Commission de Transparence of the French High Health Authority as IPF patients with forced vital capacity > 50% and carbon monoxide diffusing capacity > 35%. In agreement with CEPS, InterMune France will collect information in the form of a patient registry regarding the use of Esbriet in clinical practice.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The CEPS authorized an ex-factory reimbursed price of 1.923,08€ for a four-week treatment pack of Esbriet, corresponding to 25,000€ per patient, per year (approximately $32,000 USD at current exchange rates). Esbriet will be reimbursed by the French National Health Insurance system for the treatment of mild to moderate forms of IPF in adults.
Esbriet will be reimbursed as a “Médicament d’Exception,” which means that it will be reimbursed only for the labeled indication, defined previously by the Commission de Transparence of the French High Health Authority as IPF patients with forced vital capacity > 50% and carbon monoxide diffusing capacity > 35%. In agreement with CEPS, InterMune France will collect information in the form of a patient registry regarding the use of Esbriet in clinical practice.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- A.G. Lafley Returns as President/CEO of Procter & Gamble (PG)
- Sprint (S), SoftBank Receive Final State Regulatory Approval in Proposed Deal
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
